

# Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	9	6.6	136.6	(62.3-259.3)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.3	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	1.5	390.9	(142.7-850.8)	Female	2	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.4	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.3	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	16	21.0	76.2	(43.5-123.7)
Female	1	0.2	nc	(nc-nc)	Female	28	21.1	132.8	(88.2-192.0)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.7	nc	(nc-nc)					
Female	3	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	7.7	104.5	(45.0-205.9)	Male	5	5.3	94.9	(30.6-221.3)
Female	2	2.1	nc	(nc-nc)	Female	0	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.7	126.4	(46.1-275.0)
Female	37	28.8	128.4	(90.4-177.0)	Female	3	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.4	nc	(nc-nc)
Male	10	8.7	114.4	(54.8-210.4)	<b><u>Ovary</u></b>				
Female	5	6.7	75.0	(24.2-175.1)	Female	1	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	23	28.9	79.5	(50.4-119.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.9	nc	(nc-nc)
Male	2	4.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.2	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	6.0	nc	(nc-nc)
Male	6	3.3	180.7	(66.0-393.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.9	nc	(nc-nc)	Female	9	6.4	139.7	(63.7-265.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	93	108.3	85.8	(69.3-105.2)
Female	0	0.7	nc	(nc-nc)	Female	82	90.9	90.2	(71.8-112.0)
<b><u>Lung and Bronchus</u></b>									
Male	11	14.1	78.2	(39.0-139.9)					
Female	10	11.6	86.5	(41.4-159.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	34.8	112.0	(79.6-153.1)	Male	25	23.4	106.6	(69.0-157.4)
Female	10	15.9	62.9	(30.1-115.7)	Female	26	23.5	110.7	(72.3-162.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	7.5	159.8	(82.5-279.1)	Male	4	7.2	nc	(nc-nc)
Female	5	7.2	69.2	(22.3-161.4)	Female	12	7.2	166.6	(86.0-291.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	36	21.2	170.2	(119.2-235.6)
Female	188	177.2	106.1	(91.4-122.4)	Female	25	22.5	111.2	(71.9-164.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	6.2	nc	(nc-nc)	Male	17	17.2	98.6	(57.4-157.9)
<b><u>Colon / Rectum</u></b>					Female	12	9.5	125.9	(65.0-220.0)
Male	42	39.3	106.8	(77.0-144.4)	<b><u>Ovary</u></b>				
Female	40	48.4	82.7	(59.0-112.6)	Female	10	16.0	62.3	(29.8-114.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	18	9.4	191.8	(113.6-303.2)	Male	11	12.5	88.2	(44.0-157.8)
Female	4	3.1	nc	(nc-nc)	Female	17	16.0	106.2	(61.8-170.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	151	120.4	125.4	(106.2-147.1)
Female	7	3.2	215.6	(86.4-444.1)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	8.4	155.4	(82.7-265.7)
Male	23	20.2	114.1	(72.3-171.3)	Female	3	6.2	nc	(nc-nc)
Female	17	14.0	121.5	(70.7-194.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	6.8	88.5	(32.3-192.7)
Male	5	5.5	90.8	(29.3-212.0)	<b><u>Thyroid</u></b>				
Female	4	2.1	nc	(nc-nc)	Male	11	10.0	110.2	(54.9-197.1)
<b><u>Leukemia</u></b>					Female	37	34.7	106.5	(75.0-146.8)
Male	16	14.8	108.2	(61.8-175.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	16	13.2	121.0	(69.1-196.5)	Female	45	40.8	110.4	(80.5-147.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	16	12.6	126.5	(72.3-205.5)	Male	571	475.0	120.2	(110.6-130.5)
Female	5	5.1	97.8	(31.5-228.2)	Female	624	603.2	103.5	(95.5-111.9)
<b><u>Lung and Bronchus</u></b>									
Male	73	62.1	117.6	(92.2-147.8)					
Female	90	82.5	109.0	(87.7-134.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	10.5	85.4	(39.0-162.1)	Male	10	6.9	145.2	(69.5-267.0)
Female	4	3.4	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.1	81.6	(26.3-190.4)
Female	42	41.0	102.5	(73.9-138.6)	Female	9	4.8	186.6	(85.1-354.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	12	5.3	227.7	(117.5-397.8)
<b><u>Colon / Rectum</u></b>					Female	2	2.1	nc	(nc-nc)
Male	14	11.5	121.9	(66.6-204.5)	<b><u>Ovary</u></b>				
Female	14	10.0	139.8	(76.4-234.6)	Female	9	3.6	252.5	(115.2-479.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	5	3.4	148.0	(47.7-345.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	33	40.5	81.5	(56.1-114.5)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.5	nc	(nc-nc)
Male	8	6.1	130.7	(56.3-257.5)	Female	0	1.3	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.2	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	7.2	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.7	nc	(nc-nc)	Female	8	9.7	82.8	(35.7-163.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.9	nc	(nc-nc)	Male	130	145.3	89.5	(74.7-106.2)
Female	1	1.1	nc	(nc-nc)	Female	151	133.1	113.4	(96.0-133.0)
<b><u>Lung and Bronchus</u></b>									
Male	17	19.6	86.7	(50.5-138.9)					
Female	27	18.7	144.1	(95.0-209.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	4.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.2	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.8	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	13	22.2	58.5	(31.1-100.1)
Female	1	0.1	nc	(nc-nc)	Female	10	13.6	73.8	(35.3-135.7)
<b><u>Lung and Bronchus</u></b>									
Male	3	3.3	nc	(nc-nc)					
Female	3	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	22.9	153.0	(106.5-212.7)	Male	23	14.9	154.4	(97.8-231.6)
Female	6	7.6	79.3	(29.0-172.6)	Female	17	11.3	150.3	(87.5-240.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	4.5	201.4	(91.9-382.4)	Male	4	4.7	nc	(nc-nc)
Female	4	3.6	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	18	13.4	134.7	(79.8-213.0)
Female	111	91.9	120.8	(99.4-145.5)	Female	18	11.0	163.3	(96.8-258.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	3.1	nc	(nc-nc)	Male	11	11.3	97.4	(48.5-174.2)
<b><u>Colon / Rectum</u></b>					Female	8	4.8	167.8	(72.2-330.6)
Male	17	25.2	67.6	(39.3-108.2)	<b><u>Ovary</u></b>				
Female	25	23.0	108.6	(70.3-160.4)	Female	8	8.1	98.9	(42.6-195.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.3	94.9	(34.7-206.5)	Male	12	8.2	145.7	(75.2-254.5)
Female	2	1.5	nc	(nc-nc)	Female	9	7.5	119.5	(54.5-226.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	107	81.8	130.8	(107.2-158.1)
Female	1	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	5.4	nc	(nc-nc)
Male	11	13.1	84.2	(42.0-150.6)	Female	4	2.9	nc	(nc-nc)
Female	4	7.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.6	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	3	5.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	16.8	59.5	(28.5-109.5)
Male	16	9.2	173.2	(98.9-281.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	6.3	79.4	(25.6-185.3)	Female	26	21.4	121.3	(79.2-177.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	8.4	95.3	(41.1-187.9)	Male	354	308.9	114.6	(103.0-127.2)
Female	1	2.5	nc	(nc-nc)	Female	331	300.5	110.1	(98.6-122.7)
<b><u>Lung and Bronchus</u></b>									
Male	26	41.5	62.7	(40.9-91.8)					
Female	49	41.3	118.8	(87.9-157.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	47	34.1	137.9	(101.3-183.4)	Male	14	21.6	64.8	(35.4-108.8)
Female	23	13.2	174.0	(110.3-261.1)	Female	22	17.7	124.3	(77.9-188.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	6.0	nc	(nc-nc)	Male	6	6.9	87.5	(32.0-190.5)
Female	9	5.5	164.8	(75.2-312.8)	Female	3	6.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	24	19.0	126.2	(80.8-187.8)
Female	144	141.3	101.9	(86.0-120.0)	Female	24	18.1	132.3	(84.7-196.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.5	nc	(nc-nc)	Male	20	15.0	133.0	(81.2-205.4)
<b><u>Colon / Rectum</u></b>					Female	4	7.7	nc	(nc-nc)
Male	48	35.6	135.0	(99.5-178.9)	<b><u>Ovary</u></b>				
Female	33	38.9	84.7	(58.3-119.0)	Female	7	12.7	55.3	(22.1-113.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	8.8	147.1	(78.2-251.6)	Male	15	11.8	127.4	(71.3-210.2)
Female	4	2.6	nc	(nc-nc)	Female	14	13.2	105.8	(57.8-177.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	86	109.3	78.7	(63.0-97.2)
Female	4	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	7.9	101.1	(43.5-199.1)
Male	25	17.9	139.4	(90.2-205.7)	Female	2	5.0	nc	(nc-nc)
Female	8	11.4	70.1	(30.2-138.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	3.9	253.7	(121.5-466.7)
Male	7	5.2	134.0	(53.7-276.1)	<b><u>Thyroid</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	9	7.9	114.1	(52.1-216.6)
<b><u>Leukemia</u></b>					Female	19	23.9	79.6	(47.9-124.3)
Male	20	13.0	153.9	(94.0-237.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	10.3	nc	(nc-nc)	Female	26	33.3	78.1	(51.0-114.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	16	11.4	139.9	(79.9-227.2)	Male	478	434.6	110.0	(100.4-120.3)
Female	4	4.2	nc	(nc-nc)	Female	494	482.4	102.4	(93.6-111.8)
<b><u>Lung and Bronchus</u></b>									
Male	70	61.4	114.0	(88.8-144.0)					
Female	90	70.7	127.2	(102.3-156.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	13.9	50.2	(20.1-103.5)
Female	0	0.1	nc	(nc-nc)	Female	7	9.8	71.7	(28.7-147.7)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.0	nc	(nc-nc)					
Female	0	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	22.9	96.1	(60.2-145.5)	Male	36	14.4	250.7	(175.5-347.1)
Female	12	8.4	143.3	(73.9-250.3)	Female	29	11.1	261.2	(174.9-375.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.1	145.9	(53.3-317.6)	Male	5	4.6	109.0	(35.1-254.4)
Female	2	3.5	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	10	12.8	78.2	(37.4-143.8)
Female	99	90.8	109.0	(88.6-132.7)	Female	10	11.5	86.8	(41.5-159.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.8	nc	(nc-nc)	Male	13	10.4	125.4	(66.7-214.5)
<b><u>Colon / Rectum</u></b>					Female	7	4.9	142.8	(57.2-294.3)
Male	24	24.4	98.5	(63.1-146.5)	<b><u>Ovary</u></b>				
Female	19	25.2	75.5	(45.4-117.8)	Female	7	8.1	86.9	(34.8-179.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	6.0	83.1	(26.8-193.9)	Male	8	8.0	100.1	(43.1-197.2)
Female	0	1.6	nc	(nc-nc)	Female	7	8.4	83.6	(33.5-172.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	67	74.9	89.5	(69.3-113.6)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.3	94.0	(30.3-219.5)
Male	4	12.1	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
Female	6	7.2	83.5	(30.5-181.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.2	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	1	5.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	18	15.0	120.2	(71.2-190.0)
Male	10	8.9	112.4	(53.8-206.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	6.6	106.1	(42.5-218.6)	Female	20	20.9	95.5	(58.3-147.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	7.8	nc	(nc-nc)	Male	288	293.6	98.1	(87.1-110.1)
Female	2	2.7	nc	(nc-nc)	Female	318	306.6	103.7	(92.6-115.8)
<b><u>Lung and Bronchus</u></b>									
Male	36	40.7	88.5	(62.0-122.6)					
Female	42	43.8	95.9	(69.1-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	17.2	81.2	(44.4-136.3)	Male	6	11.1	53.9	(19.7-117.3)
Female	2	5.4	nc	(nc-nc)	Female	8	7.9	101.5	(43.7-200.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	14	9.8	142.8	(78.0-239.6)
Female	48	63.3	75.8	(55.9-100.5)	Female	5	7.7	64.5	(20.8-150.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	5	8.0	62.3	(20.1-145.4)
<b><u>Colon / Rectum</u></b>					Female	5	3.3	150.0	(48.3-350.0)
Male	13	18.2	71.6	(38.1-122.4)	<b><u>Ovary</u></b>				
Female	10	16.0	62.3	(29.8-114.6)	Female	7	5.6	125.9	(50.4-259.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	4.7	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	9	5.4	166.2	(75.9-315.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	40	60.0	66.7	(47.6-90.8)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.0	nc	(nc-nc)
Male	6	9.6	62.7	(22.9-136.5)	Female	1	2.0	nc	(nc-nc)
Female	0	4.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.9	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	11.4	96.5	(48.1-172.7)
Male	6	6.7	89.2	(32.6-194.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	4.4	nc	(nc-nc)	Female	11	14.8	74.3	(37.0-133.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	6.1	nc	(nc-nc)	Male	156	228.1	68.4	(58.1-80.0)
Female	0	1.8	nc	(nc-nc)	Female	158	210.1	75.2	(63.9-87.9)
<b><u>Lung and Bronchus</u></b>									
Male	20	32.1	62.2	(38.0-96.1)					
Female	25	30.1	83.1	(53.8-122.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	17.9	66.9	(34.5-116.8)	Male	11	12.1	90.7	(45.2-162.4)
Female	7	6.0	116.3	(46.6-239.6)	Female	18	9.5	189.3	(112.1-299.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.7	nc	(nc-nc)	Male	7	3.9	181.5	(72.7-373.9)
Female	1	3.0	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	15	10.8	138.4	(77.4-228.3)
Female	86	77.3	111.2	(88.9-137.3)	Female	8	8.9	89.5	(38.6-176.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.7	nc	(nc-nc)	Male	6	9.6	62.2	(22.7-135.5)
<b><u>Colon / Rectum</u></b>					Female	1	3.9	nc	(nc-nc)
Male	13	20.5	63.6	(33.8-108.7)	<b><u>Ovary</u></b>				
Female	9	18.8	47.8	(21.8-90.8)	Female	8	6.7	119.6	(51.5-235.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.2	nc	(nc-nc)	Male	9	6.7	134.7	(61.5-255.7)
Female	2	1.2	nc	(nc-nc)	Female	8	6.1	132.0	(56.8-260.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	68	71.0	95.7	(74.3-121.3)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.4	nc	(nc-nc)
Male	6	11.1	54.2	(19.8-117.9)	Female	2	2.4	nc	(nc-nc)
Female	8	5.8	137.2	(59.1-270.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	2.0	246.9	(79.6-576.3)
Male	1	3.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	8	5.0	159.9	(68.8-315.0)
<b><u>Leukemia</u></b>					Female	26	14.7	177.0	(115.6-259.4)
Male	7	7.3	95.3	(38.2-196.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	5.2	96.2	(31.0-224.5)	Female	16	17.7	90.2	(51.5-146.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	7.1	nc	(nc-nc)	Male	220	255.4	86.1	(75.1-98.3)
Female	1	2.0	nc	(nc-nc)	Female	261	248.3	105.1	(92.8-118.7)
<b><u>Lung and Bronchus</u></b>									
Male	18	33.5	53.7	(31.8-84.8)					
Female	35	32.7	107.0	(74.5-148.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	4.8	125.0	(45.7-272.2)	Male	3	3.0	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	16	16.4	97.6	(55.7-158.5)	Female	1	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.8	nc	(nc-nc)
Male	4	5.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	3.9	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	20	16.5	121.2	(74.0-187.2)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.1	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.8	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.1	nc	(nc-nc)	Female	5	4.0	125.4	(40.4-292.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	56	62.2	90.0	(68.0-116.9)
Female	1	0.5	nc	(nc-nc)	Female	59	53.4	110.5	(84.2-142.6)
<b><u>Lung and Bronchus</u></b>									
Male	5	8.5	58.5	(18.9-136.6)					
Female	15	7.7	195.2	(109.2-322.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	4	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	9	11.0	82.1	(37.5-155.9)	Female	2	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.6	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	3.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	14	10.2	137.6	(75.2-230.9)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	1.8	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.8	nc	(nc-nc)	Female	6	2.6	229.3	(83.7-499.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	40	36.6	109.2	(78.0-148.7)
Female	0	0.3	nc	(nc-nc)	Female	44	37.3	118.1	(85.8-158.6)
<b><u>Lung and Bronchus</u></b>									
Male	4	5.0	nc	(nc-nc)					
Female	5	5.5	91.6	(29.5-213.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	5.1	156.7	(67.5-308.8)	Male	5	3.2	156.0	(50.3-364.2)
Female	1	1.6	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	24	19.4	123.6	(79.1-183.8)	Female	4	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.0	nc	(nc-nc)
Male	8	5.5	144.7	(62.3-285.1)	<b><u>Ovary</u></b>				
Female	3	4.7	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	19	16.7	113.8	(68.5-177.7)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.2	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	3.4	147.1	(47.4-343.3)
Male	4	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	66	65.7	100.4	(77.7-127.7)
Female	0	0.5	nc	(nc-nc)	Female	63	62.4	100.9	(77.6-129.1)
<b><u>Lung and Bronchus</u></b>									
Male	5	9.0	55.5	(17.9-129.6)					
Female	6	8.7	69.0	(25.2-150.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	6.0	201.4	(103.9-351.8)	Male	3	4.8	nc	(nc-nc)
Female	6	1.9	314.3	(114.8-684.0)	Female	1	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	4.3	186.7	(80.4-367.9)
Female	28	23.3	119.9	(79.7-173.3)	Female	2	2.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.2	nc	(nc-nc)
Male	10	7.7	129.3	(61.9-237.8)	<b><u>Ovary</u></b>				
Female	8	5.8	136.9	(58.9-269.7)	Female	2	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	27	24.0	112.3	(74.0-163.4)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.6	nc	(nc-nc)
Male	6	4.4	136.6	(49.9-297.3)	Female	1	0.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.8	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.6	109.4	(35.2-255.3)
Male	2	2.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.6	nc	(nc-nc)	Female	12	5.3	227.4	(117.4-397.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	2.7	300.5	(129.4-592.1)	Male	120	93.8	127.9	(106.0-152.9)
Female	0	0.6	nc	(nc-nc)	Female	94	76.5	122.9	(99.3-150.5)
<b><u>Lung and Bronchus</u></b>									
Male	22	11.2	196.9	(123.4-298.2)					
Female	11	10.3	106.4	(53.0-190.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	34.5	112.9	(80.3-154.4)	Male	17	22.6	75.2	(43.8-120.5)
Female	14	12.5	111.7	(61.0-187.5)	Female	20	18.4	108.9	(66.5-168.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	7.0	99.4	(39.8-204.8)	Male	11	7.0	157.2	(78.4-281.3)
Female	2	5.8	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	29	20.5	141.5	(94.8-203.2)
Female	151	142.0	106.3	(90.0-124.7)	Female	15	17.7	84.6	(47.3-139.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	5.0	nc	(nc-nc)	Male	12	16.4	73.1	(37.7-127.6)
<b><u>Colon / Rectum</u></b>					Female	5	7.5	67.1	(21.6-156.5)
Male	35	38.3	91.3	(63.6-126.9)	<b><u>Ovary</u></b>				
Female	27	38.7	69.9	(46.0-101.6)	Female	13	12.5	104.0	(55.3-177.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	9.1	131.6	(67.9-229.9)	Male	9	12.2	73.7	(33.6-140.0)
Female	5	2.4	206.1	(66.4-481.0)	Female	11	12.6	87.2	(43.5-156.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	124	115.1	107.7	(89.6-128.4)
Female	4	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	8.2	nc	(nc-nc)
Male	28	19.5	143.9	(95.6-208.0)	Female	2	5.0	nc	(nc-nc)
Female	11	11.2	98.6	(49.2-176.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	5.3	113.7	(41.5-247.5)
Male	0	5.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	15	9.2	162.6	(90.9-268.2)
<b><u>Leukemia</u></b>					Female	14	27.6	50.8	(27.7-85.2)
Male	11	14.4	76.6	(38.2-137.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	10.6	142.0	(79.4-234.2)	Female	27	31.1	86.8	(57.2-126.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	11.8	92.8	(46.3-166.1)	Male	483	457.9	105.5	(96.3-115.3)
Female	3	4.0	nc	(nc-nc)	Female	445	478.4	93.0	(84.6-102.1)
<b><u>Lung and Bronchus</u></b>									
Male	59	60.7	97.2	(74.0-125.4)					
Female	64	66.0	97.0	(74.7-123.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	8	8.9	90.0	(38.7-177.3)	Female	0	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	7.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	12	25.2	47.7	(24.6-83.3)
Female	0	0.2	nc	(nc-nc)	Female	18	28.0	64.4	(38.1-101.8)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.1	nc	(nc-nc)					
Female	1	3.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	24.4	102.4	(66.2-151.1)	Male	11	15.1	72.9	(36.4-130.5)
Female	13	10.1	128.7	(68.5-220.2)	Female	8	12.1	66.1	(28.4-130.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.2	118.3	(38.1-276.0)	Male	1	4.7	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	Female	5	4.4	114.6	(36.9-267.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	13	13.4	97.1	(51.7-166.1)
Female	88	95.8	91.8	(73.7-113.2)	Female	14	13.1	107.0	(58.5-179.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.9	nc	(nc-nc)	Male	6	10.5	57.4	(21.0-125.0)
<b><u>Colon / Rectum</u></b>					Female	7	5.3	131.0	(52.5-270.0)
Male	23	25.5	90.1	(57.1-135.2)	<b><u>Ovary</u></b>				
Female	30	29.6	101.3	(68.3-144.6)	Female	8	8.6	92.8	(39.9-182.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	6.2	112.6	(45.1-231.9)	Male	10	8.4	118.4	(56.7-217.8)
Female	0	1.9	nc	(nc-nc)	Female	15	10.2	147.1	(82.3-242.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	81	77.8	104.1	(82.7-129.4)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	5.6	196.7	(98.1-352.0)
Male	16	12.5	128.2	(73.2-208.2)	Female	4	3.9	nc	(nc-nc)
Female	7	8.0	87.7	(35.1-180.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	2.6	229.3	(83.7-499.2)
Male	4	3.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	19	15.0	126.6	(76.2-197.7)
Male	12	9.3	128.5	(66.3-224.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	7.6	131.5	(62.9-241.8)	Female	19	21.4	88.9	(53.5-138.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	7.8	76.8	(28.0-167.1)	Male	325	307.0	105.8	(94.7-118.0)
Female	0	3.0	nc	(nc-nc)	Female	320	339.8	94.2	(84.1-105.1)
<b><u>Lung and Bronchus</u></b>									
Male	54	43.3	124.7	(93.6-162.7)					
Female	40	51.6	77.6	(55.4-105.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	38	49.9	76.2	(53.9-104.6)	Male	30	35.8	83.9	(56.6-119.8)
Female	19	19.7	96.3	(58.0-150.5)	Female	20	34.6	57.8	(35.3-89.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	12.5	64.1	(27.6-126.3)	Male	11	10.2	107.7	(53.7-192.7)
Female	13	10.5	124.4	(66.2-212.7)	Female	11	8.9	123.0	(61.3-220.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	40	31.9	125.2	(89.5-170.5)
Female	176	227.3	77.4	(66.4-89.8)	Female	21	29.4	71.5	(44.2-109.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	10.1	99.3	(47.5-182.7)	Male	25	24.0	104.3	(67.5-154.0)
<b><u>Colon / Rectum</u></b>					Female	11	12.0	91.7	(45.7-164.0)
Male	52	56.1	92.6	(69.2-121.5)	<b><u>Ovary</u></b>				
Female	48	61.4	78.2	(57.7-103.7)	Female	23	20.7	110.9	(70.3-166.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	12.9	85.6	(42.6-153.1)	Male	19	17.3	109.7	(66.0-171.3)
Female	5	3.8	130.7	(42.1-304.9)	Female	21	19.8	106.1	(65.6-162.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	11	7.5	146.9	(73.3-262.9)	Male	144	157.2	91.6	(77.2-107.8)
Female	4	6.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	12.0	125.1	(70.0-206.3)
Male	36	29.1	123.8	(86.7-171.3)	Female	14	7.9	178.0	(97.3-298.7)
Female	24	18.3	131.5	(84.2-195.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	17.5	40.1	(16.1-82.6)
Male	11	7.6	145.6	(72.6-260.5)	<b><u>Thyroid</u></b>				
Female	2	2.5	nc	(nc-nc)	Male	14	17.0	82.2	(44.9-137.9)
<b><u>Leukemia</u></b>					Female	50	58.7	85.1	(63.2-112.3)
Male	16	22.7	70.5	(40.3-114.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	20	18.1	110.2	(67.3-170.2)	Female	48	49.4	97.2	(71.7-128.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	26	17.1	152.4	(99.5-223.3)	Male	669	683.0	97.9	(90.7-105.7)
Female	16	6.3	252.3	(144.1-409.8)	Female	723	792.0	91.3	(84.8-98.2)
<b><u>Lung and Bronchus</u></b>									
Male	105	87.5	120.0	(98.1-145.2)					
Female	100	103.8	96.3	(78.4-117.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	21.0	90.6	(54.5-141.4)	Male	18	12.8	140.6	(83.3-222.2)
Female	11	8.2	134.0	(66.8-239.7)	Female	10	11.1	90.4	(43.3-166.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	9	11.4	78.8	(36.0-149.6)
Female	96	85.3	112.5	(91.1-137.4)	Female	11	11.1	98.9	(49.3-177.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	2.7	183.7	(59.2-428.7)	Male	6	8.9	67.7	(24.7-147.4)
<b><u>Colon / Rectum</u></b>					Female	6	4.6	129.6	(47.3-282.2)
Male	21	22.0	95.6	(59.2-146.2)	<b><u>Ovary</u></b>				
Female	32	24.0	133.1	(91.0-187.9)	Female	3	7.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.3	nc	(nc-nc)	Male	3	7.2	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	8	8.2	97.9	(42.2-192.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	62	64.7	95.8	(73.4-122.8)
Female	0	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.8	104.0	(33.5-242.8)
Male	7	10.5	66.5	(26.6-137.0)	Female	2	3.1	nc	(nc-nc)
Female	8	7.0	114.8	(49.4-226.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.0	nc	(nc-nc)
Male	6	3.0	197.2	(72.0-429.2)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	15.4	71.4	(35.6-127.7)
Male	5	7.9	63.7	(20.5-148.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	6.6	121.7	(52.4-239.8)	Female	26	19.5	133.2	(87.0-195.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	6.7	nc	(nc-nc)	Male	239	259.9	92.0	(80.7-104.4)
Female	0	2.5	nc	(nc-nc)	Female	304	295.9	102.7	(91.5-114.9)
<b><u>Lung and Bronchus</u></b>									
Male	37	36.6	101.2	(71.3-139.5)					
Female	40	43.2	92.5	(66.1-126.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.7	74.2	(23.9-173.0)	Male	1	4.4	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	20	26.1	76.6	(46.8-118.4)	Female	2	3.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	7	7.2	97.7	(39.1-201.3)	<b><u>Ovary</u></b>				
Female	9	6.2	145.2	(66.3-275.6)	Female	2	2.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	25	23.7	105.6	(68.3-155.8)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.6	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.9	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	4.9	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.7	nc	(nc-nc)	Female	6	6.1	98.6	(36.0-214.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	74	90.3	81.9	(64.3-102.8)
Female	0	0.7	nc	(nc-nc)	Female	72	84.6	85.1	(66.6-107.2)
<b><u>Lung and Bronchus</u></b>									
Male	5	12.2	41.0	(13.2-95.8)					
Female	13	11.9	109.5	(58.2-187.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	10.3	78.0	(33.6-153.8)	Male	8	6.8	118.4	(51.0-233.3)
Female	2	3.2	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
Female	45	40.3	111.7	(81.5-149.5)	Female	4	4.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	6	5.1	116.6	(42.6-253.7)
<b><u>Colon / Rectum</u></b>					Female	2	2.0	nc	(nc-nc)
Male	6	11.6	51.8	(18.9-112.8)	<b><u>Ovary</u></b>				
Female	12	10.0	120.2	(62.0-209.9)	Female	1	3.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	5	3.1	159.3	(51.3-371.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	37	35.7	103.7	(73.0-142.9)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.5	nc	(nc-nc)
Male	8	5.9	135.5	(58.3-267.0)	Female	1	1.3	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.3	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.7	181.9	(58.6-424.6)
<b><u>Leukemia</u></b>					Female	6	7.8	77.0	(28.1-167.5)
Male	5	4.2	119.1	(38.4-278.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.8	nc	(nc-nc)	Female	5	8.9	55.9	(18.0-130.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.8	nc	(nc-nc)	Male	129	138.3	93.3	(77.9-110.8)
Female	0	1.0	nc	(nc-nc)	Female	117	129.7	90.2	(74.6-108.1)
<b><u>Lung and Bronchus</u></b>									
Male	13	18.2	71.5	(38.1-122.3)					
Female	18	17.1	105.2	(62.3-166.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	16.1	111.9	(66.3-176.9)	Male	6	10.4	57.4	(21.0-125.0)
Female	10	6.6	152.3	(72.9-280.0)	Female	4	9.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	10	9.4	106.9	(51.2-196.6)
Female	59	69.7	84.7	(64.5-109.2)	Female	13	9.1	143.5	(76.3-245.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.4	nc	(nc-nc)	Male	10	7.5	134.2	(64.3-246.8)
<b><u>Colon / Rectum</u></b>					Female	1	3.8	nc	(nc-nc)
Male	16	17.5	91.7	(52.4-148.9)	<b><u>Ovary</u></b>				
Female	21	20.0	104.9	(64.9-160.4)	Female	7	6.3	111.5	(44.7-229.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	4.2	nc	(nc-nc)	Male	7	5.6	124.1	(49.7-255.7)
Female	1	1.3	nc	(nc-nc)	Female	2	6.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	50	52.1	95.9	(71.2-126.5)
Female	3	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	3.8	158.2	(57.8-344.4)
Male	7	8.8	79.9	(32.0-164.7)	Female	5	2.6	191.1	(61.6-446.0)
Female	10	5.6	180.0	(86.2-331.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.4	nc	(nc-nc)
Male	8	2.5	326.3	(140.5-642.9)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	1	4.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	13.1	76.2	(36.5-140.1)
Male	8	6.7	120.1	(51.7-236.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	5.5	201.1	(100.3-359.9)	Female	20	15.7	127.6	(77.9-197.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	5.6	125.4	(50.2-258.4)	Male	233	210.3	110.8	(97.0-126.0)
Female	0	2.0	nc	(nc-nc)	Female	233	240.4	96.9	(84.9-110.2)
<b><u>Lung and Bronchus</u></b>									
Male	43	28.5	150.8	(109.1-203.1)					
Female	28	33.0	84.8	(56.3-122.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	11.0	99.8	(49.7-178.5)	Male	5	7.0	71.2	(22.9-166.2)
Female	2	4.1	nc	(nc-nc)	Female	3	5.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.3	nc	(nc-nc)
Female	40	42.5	94.0	(67.2-128.0)	Female	6	5.6	107.8	(39.4-234.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.3	nc	(nc-nc)
Male	8	11.9	67.4	(29.0-132.8)	<b><u>Ovary</u></b>				
Female	11	12.4	88.8	(44.3-158.9)	Female	4	3.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	32	35.2	91.0	(62.2-128.4)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.6	nc	(nc-nc)
Male	7	5.9	118.5	(47.5-244.2)	Female	2	1.6	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.4	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	7.6	65.7	(21.2-153.3)
Male	2	4.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	3.2	186.2	(68.0-405.3)	Female	8	9.4	85.4	(36.8-168.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.7	nc	(nc-nc)	Male	117	141.7	82.6	(68.3-99.0)
Female	1	1.3	nc	(nc-nc)	Female	121	146.4	82.6	(68.6-98.7)
<b><u>Lung and Bronchus</u></b>									
Male	19	19.3	98.4	(59.2-153.6)					
Female	16	20.7	77.1	(44.0-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	11.2	178.3	(108.9-275.4)	Male	10	7.7	129.8	(62.1-238.7)
Female	11	4.2	263.0	(131.1-470.5)	Female	4	6.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
Female	46	47.5	96.9	(71.0-129.3)	Female	6	5.9	101.6	(37.1-221.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	10	5.8	171.5	(82.1-315.5)
<b><u>Colon / Rectum</u></b>					Female	3	2.5	nc	(nc-nc)
Male	10	12.4	80.8	(38.7-148.6)	<b><u>Ovary</u></b>				
Female	11	12.5	87.9	(43.8-157.2)	Female	1	4.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	3.2	155.4	(50.1-362.7)	Male	5	4.1	122.6	(39.5-286.0)
Female	1	0.8	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	32	42.4	75.5	(51.6-106.6)
Female	2	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.7	nc	(nc-nc)
Male	10	6.9	145.9	(69.8-268.3)	Female	2	1.6	nc	(nc-nc)
Female	8	3.7	215.4	(92.8-424.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.9	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	9.0	66.7	(24.4-145.2)
Male	15	4.7	316.8	(177.2-522.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.5	141.4	(45.6-330.0)	Female	18	10.8	167.2	(99.0-264.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	4.3	140.7	(51.4-306.2)	Male	168	158.1	106.2	(90.8-123.6)
Female	1	1.4	nc	(nc-nc)	Female	170	159.5	106.6	(91.2-123.9)
<b><u>Lung and Bronchus</u></b>									
Male	27	20.9	129.0	(85.0-187.7)					
Female	24	22.1	108.7	(69.6-161.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	94	122.5	76.7	(62.0-93.9)	Male	36	81.2	44.3	(31.0-61.4)
Female	40	47.7	83.9	(59.9-114.3)	Female	33	72.8	45.3	(31.2-63.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	27	27.2	99.3	(65.4-144.5)	Male	25	25.1	99.8	(64.6-147.3)
Female	22	24.0	91.7	(57.5-138.9)	Female	26	21.7	120.0	(78.4-175.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	7	4.2	166.1	(66.6-342.3)	Male	77	73.5	104.8	(82.7-131.0)
Female	512	546.6	93.7	(85.7-102.1)	Female	67	68.6	97.6	(75.6-124.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	35	19.9	175.5	(122.2-244.1)	Male	67	58.5	114.5	(88.7-145.4)
<b><u>Colon / Rectum</u></b>					Female	20	29.0	68.9	(42.1-106.4)
Male	150	134.8	111.3	(94.2-130.6)	<b><u>Ovary</u></b>				
Female	158	145.3	108.7	(92.4-127.1)	Female	32	49.0	65.3	(44.7-92.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	37	32.7	113.2	(79.7-156.1)	Male	48	43.3	110.7	(81.6-146.8)
Female	12	9.3	129.0	(66.6-225.3)	Female	43	47.8	89.9	(65.1-121.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	16	12.1	132.6	(75.8-215.4)	Male	388	414.2	93.7	(84.6-103.5)
Female	16	10.8	148.2	(84.7-240.7)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	34	29.0	117.3	(81.2-163.9)
Male	85	69.2	122.8	(98.1-151.8)	Female	25	18.7	133.7	(86.5-197.3)
Female	51	43.3	117.8	(87.7-154.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	12	22.6	53.1	(27.4-92.8)
Male	17	19.0	89.5	(52.1-143.4)	<b><u>Thyroid</u></b>				
Female	7	6.4	109.8	(44.0-226.1)	Male	12	33.6	35.7	(18.4-62.4)
<b><u>Leukemia</u></b>					Female	81	111.9	72.4	(57.5-90.0)
Male	52	53.1	98.0	(73.2-128.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	41	42.0	97.5	(70.0-132.3)	Female	120	124.0	96.8	(80.2-115.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	58	43.3	134.0	(101.8-173.3)	Male	1620	1648.6	98.3	(93.5-103.2)
Female	16	15.5	103.0	(58.9-167.3)	Female	1758	1853.7	94.8	(90.5-99.4)
<b><u>Lung and Bronchus</u></b>									
Male	253	218.7	115.7	(101.8-130.8)					
Female	254	251.7	100.9	(88.9-114.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	7.9	139.0	(69.3-248.7)	Male	5	5.3	94.1	(30.3-219.7)
Female	4	2.7	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.8	145.1	(58.1-299.0)
Female	42	33.8	124.2	(89.5-167.9)	Female	2	3.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	6	9.1	65.8	(24.0-143.2)	<b><u>Ovary</u></b>				
Female	4	8.5	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	6	2.9	207.2	(75.7-451.0)
Female	0	0.5	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	49	30.3	161.6	(119.6-213.7)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	7	4.9	143.3	(57.4-295.3)	Female	1	1.1	nc	(nc-nc)
Female	5	2.5	197.8	(63.7-461.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.1	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	6.5	92.3	(33.7-200.8)
Male	6	3.3	182.7	(66.7-397.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.3	nc	(nc-nc)	Female	9	7.5	120.1	(54.8-227.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.0	nc	(nc-nc)	Male	134	111.5	120.2	(100.7-142.3)
Female	0	0.9	nc	(nc-nc)	Female	111	109.1	101.7	(83.7-122.5)
<b><u>Lung and Bronchus</u></b>									
Male	11	14.5	76.1	(37.9-136.1)					
Female	18	14.1	127.8	(75.7-202.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	7	1.9	362.5	(145.2-747.0)
Female	2	1.3	nc	(nc-nc)	Female	6	1.5	406.8	(148.6-885.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	11	11.8	93.4	(46.6-167.1)	Female	3	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.7	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	8	3.8	212.0	(91.3-417.7)	Female	3	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	15	10.5	143.2	(80.1-236.3)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.7	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	45	40.1	112.2	(81.8-150.1)
Female	0	0.4	nc	(nc-nc)	Female	48	43.0	111.7	(82.4-148.2)
<b><u>Lung and Bronchus</u></b>									
Male	1	5.8	nc	(nc-nc)					
Female	1	6.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	30.5	65.5	(40.0-101.2)	Male	11	18.5	59.6	(29.7-106.6)
Female	13	10.0	129.8	(69.1-222.0)	Female	14	13.4	104.7	(57.2-175.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	5.1	138.0	(55.3-284.3)	Male	7	5.9	119.3	(47.8-245.8)
Female	4	4.1	nc	(nc-nc)	Female	5	4.5	112.1	(36.1-261.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	16	16.4	97.4	(55.7-158.2)
Female	133	104.9	126.7	(106.1-150.2)	Female	10	13.6	73.5	(35.2-135.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	3.4	175.7	(64.1-382.4)	Male	15	12.8	117.6	(65.8-193.9)
<b><u>Colon / Rectum</u></b>					Female	8	5.7	140.1	(60.3-276.1)
Male	36	31.6	113.9	(79.8-157.7)	<b><u>Ovary</u></b>				
Female	33	30.1	109.7	(75.5-154.1)	Female	13	9.4	138.3	(73.6-236.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	7.7	90.3	(36.2-186.2)	Male	6	10.5	57.1	(20.9-124.3)
Female	1	1.9	nc	(nc-nc)	Female	11	10.1	108.9	(54.3-194.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	65	96.6	67.3	(51.9-85.8)
Female	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	6.9	159.3	(79.4-285.1)
Male	14	15.1	92.6	(50.6-155.3)	Female	5	3.9	128.0	(41.2-298.6)
Female	9	8.4	107.1	(48.9-203.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.0	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	10	6.3	157.6	(75.5-289.9)
<b><u>Leukemia</u></b>					Female	21	18.2	115.2	(71.3-176.0)
Male	16	11.5	139.4	(79.6-226.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	7.9	126.5	(60.6-232.7)	Female	35	23.9	146.2	(101.8-203.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	9.7	62.0	(22.6-135.0)	Male	351	378.8	92.7	(83.2-102.9)
Female	4	3.1	nc	(nc-nc)	Female	420	360.5	116.5	(105.6-128.2)
<b><u>Lung and Bronchus</u></b>									
Male	46	53.2	86.5	(63.3-115.4)					
Female	52	51.2	101.5	(75.8-133.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	31.6	91.8	(61.5-131.9)	Male	17	20.1	84.4	(49.1-135.1)
Female	13	12.6	102.9	(54.7-175.9)	Female	22	17.1	128.3	(80.4-194.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.9	102.1	(37.3-222.2)	Male	8	6.4	125.7	(54.1-247.8)
Female	8	5.2	152.4	(65.6-300.3)	Female	7	5.7	123.4	(49.4-254.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	15	18.0	83.6	(46.7-137.8)
Female	139	136.1	102.1	(85.9-120.6)	Female	20	17.4	115.0	(70.2-177.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.5	134.4	(49.1-292.5)	Male	14	14.3	97.7	(53.4-163.9)
<b><u>Colon / Rectum</u></b>					Female	5	7.3	68.3	(22.0-159.4)
Male	34	33.7	100.9	(69.8-140.9)	<b><u>Ovary</u></b>				
Female	36	38.0	94.7	(66.3-131.1)	Female	12	12.1	99.2	(51.2-173.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	8.3	132.0	(65.8-236.2)	Male	13	11.1	117.6	(62.5-201.1)
Female	5	2.5	202.8	(65.4-473.4)	Female	18	12.8	140.3	(83.1-221.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	98	106.7	91.9	(74.6-112.0)
Female	5	1.9	269.6	(86.9-629.1)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	7.4	67.9	(21.9-158.4)
Male	27	17.1	158.0	(104.1-229.8)	Female	8	4.9	163.2	(70.3-321.5)
Female	15	10.8	138.4	(77.4-228.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	4.1	nc	(nc-nc)
Male	9	4.9	184.8	(84.3-350.9)	<b><u>Thyroid</u></b>				
Female	2	1.6	nc	(nc-nc)	Male	9	7.6	117.8	(53.7-223.6)
<b><u>Leukemia</u></b>					Female	33	23.7	139.3	(95.9-195.7)
Male	13	12.4	104.8	(55.7-179.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	10.0	89.7	(40.9-170.3)	Female	20	31.1	64.2	(39.2-99.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	10.7	102.5	(51.1-183.4)	Male	431	412.2	104.6	(94.9-114.9)
Female	1	4.0	nc	(nc-nc)	Female	485	463.1	104.7	(95.6-114.5)
<b><u>Lung and Bronchus</u></b>									
Male	65	56.6	114.8	(88.6-146.3)					
Female	56	66.0	84.8	(64.1-110.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	7.3	192.1	(104.9-322.3)	Male	4	4.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	34	29.2	116.4	(80.6-162.7)	Female	4	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.5	nc	(nc-nc)
Male	7	8.0	87.2	(34.9-179.6)	<b><u>Ovary</u></b>				
Female	9	6.7	133.8	(61.1-254.1)	Female	6	2.5	239.5	(87.5-521.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	35	24.5	142.6	(99.3-198.3)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.7	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.8	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.6	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.9	nc	(nc-nc)	Female	10	6.9	144.6	(69.2-266.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	90	95.9	93.8	(75.4-115.3)
Female	1	0.8	nc	(nc-nc)	Female	103	92.7	111.1	(90.7-134.8)
<b><u>Lung and Bronchus</u></b>									
Male	4	12.9	nc	(nc-nc)					
Female	10	12.3	81.1	(38.8-149.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	10.5	180.4	(108.6-281.7)	Male	9	6.9	130.8	(59.7-248.4)
Female	4	4.0	nc	(nc-nc)	Female	8	5.5	144.5	(62.2-284.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.1	82.3	(26.5-192.0)
Female	42	44.9	93.6	(67.5-126.5)	Female	5	5.6	89.7	(28.9-209.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	5	5.1	97.7	(31.5-228.1)
<b><u>Colon / Rectum</u></b>					Female	1	2.4	nc	(nc-nc)
Male	11	11.3	97.0	(48.3-173.5)	<b><u>Ovary</u></b>				
Female	8	11.8	68.1	(29.3-134.1)	Female	2	4.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	5	3.9	127.0	(40.9-296.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	0.7	nc	(nc-nc)	Male	40	38.2	104.8	(74.9-142.7)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.5	nc	(nc-nc)
Male	7	6.0	117.0	(46.9-241.0)	Female	1	1.5	nc	(nc-nc)
Female	7	3.6	196.2	(78.6-404.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	7.9	63.4	(20.4-148.0)
Male	5	4.2	118.2	(38.1-275.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.2	nc	(nc-nc)	Female	18	10.4	173.5	(102.8-274.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	3.9	nc	(nc-nc)	Male	150	142.4	105.4	(89.2-123.6)
Female	2	1.3	nc	(nc-nc)	Female	135	150.4	89.8	(75.3-106.3)
<b><u>Lung and Bronchus</u></b>									
Male	19	19.4	98.2	(59.1-153.3)					
Female	15	21.7	69.0	(38.6-113.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	19.9	80.4	(45.9-130.6)	Male	19	13.0	145.7	(87.7-227.6)
Female	0	6.1	nc	(nc-nc)	Female	8	9.2	87.1	(37.5-171.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.0	150.4	(54.9-327.3)	Male	5	4.2	120.5	(38.8-281.1)
Female	5	3.0	169.3	(54.6-395.1)	Female	2	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	10	11.6	86.0	(41.2-158.3)
Female	122	75.8	161.0	(133.7-192.2)	Female	11	8.9	123.9	(61.8-221.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.6	nc	(nc-nc)	Male	5	9.8	51.1	(16.5-119.1)
<b><u>Colon / Rectum</u></b>					Female	4	3.8	nc	(nc-nc)
Male	25	21.8	114.5	(74.1-169.1)	<b><u>Ovary</u></b>				
Female	14	19.0	73.8	(40.3-123.9)	Female	6	6.5	91.9	(33.6-200.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.5	nc	(nc-nc)	Male	9	7.2	125.5	(57.3-238.2)
Female	1	1.2	nc	(nc-nc)	Female	3	6.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	72	71.6	100.6	(78.7-126.7)
Female	2	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.7	nc	(nc-nc)
Male	14	11.5	121.7	(66.5-204.2)	Female	1	2.4	nc	(nc-nc)
Female	6	5.8	103.6	(37.8-225.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.1	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	6	5.1	118.3	(43.2-257.5)
<b><u>Leukemia</u></b>					Female	17	13.8	122.8	(71.5-196.6)
Male	5	8.1	61.8	(19.9-144.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	5.2	154.7	(66.6-304.7)	Female	16	17.1	93.6	(53.5-152.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	7.3	nc	(nc-nc)	Male	228	269.5	84.6	(74.0-96.3)
Female	3	2.0	nc	(nc-nc)	Female	286	245.0	116.8	(103.6-131.1)
<b><u>Lung and Bronchus</u></b>									
Male	10	36.8	27.2	(13.0-50.0)					
Female	31	33.2	93.4	(63.4-132.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	3.5	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	18	10.9	164.9	(97.7-260.6)	Female	0	1.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.6	nc	(nc-nc)
Male	3	3.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	3.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	10	11.5	86.8	(41.5-159.6)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.4	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.9	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	33	46.1	71.6	(49.3-100.6)
Female	0	0.3	nc	(nc-nc)	Female	31	38.7	80.1	(54.4-113.8)
<b><u>Lung and Bronchus</u></b>									
Male	2	5.9	nc	(nc-nc)					
Female	3	5.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	9.3	118.7	(59.2-212.4)	Male	9	6.4	141.2	(64.4-268.1)
Female	6	2.3	264.1	(96.4-574.8)	Female	4	4.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.7	140.1	(60.3-276.1)
Female	39	33.9	115.1	(81.8-157.3)	Female	4	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	2	5.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.6	nc	(nc-nc)
Male	7	10.6	66.1	(26.5-136.2)	<b><u>Ovary</u></b>				
Female	8	7.0	113.6	(48.9-223.9)	Female	1	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	27	37.9	71.3	(47.0-103.8)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.3	nc	(nc-nc)
Male	6	5.9	100.9	(36.9-219.7)	Female	2	0.9	nc	(nc-nc)
Female	6	2.5	244.4	(89.3-532.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.1	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	7.1	99.1	(39.7-204.3)
Male	7	3.9	180.3	(72.2-371.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.1	nc	(nc-nc)	Female	14	7.9	177.4	(96.9-297.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.7	nc	(nc-nc)	Male	127	134.6	94.3	(78.6-112.2)
Female	1	0.8	nc	(nc-nc)	Female	125	104.3	119.8	(99.7-142.8)
<b><u>Lung and Bronchus</u></b>									
Male	19	17.5	108.5	(65.3-169.4)					
Female	14	13.0	107.7	(58.8-180.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	16.2	160.8	(105.0-235.6)	Male	14	10.1	138.7	(75.8-232.8)
Female	13	6.2	211.2	(112.3-361.2)	Female	16	8.6	187.1	(106.9-303.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	16	9.0	177.2	(101.2-287.7)
Female	83	67.3	123.4	(98.3-153.0)	Female	12	8.5	141.2	(72.9-246.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.2	nc	(nc-nc)	Male	6	7.3	82.6	(30.2-179.8)
<b><u>Colon / Rectum</u></b>					Female	4	3.6	nc	(nc-nc)
Male	16	17.3	92.3	(52.7-149.9)	<b><u>Ovary</u></b>				
Female	19	18.7	101.7	(61.2-158.8)	Female	3	6.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.2	nc	(nc-nc)	Male	6	5.6	106.3	(38.8-231.5)
Female	2	1.2	nc	(nc-nc)	Female	6	6.2	97.5	(35.6-212.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	50	52.3	95.6	(70.9-126.0)
Female	3	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	3.7	nc	(nc-nc)
Male	11	8.5	129.8	(64.7-232.3)	Female	1	2.4	nc	(nc-nc)
Female	6	5.3	112.3	(41.0-244.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.7	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	8	3.7	216.6	(93.3-426.8)
<b><u>Leukemia</u></b>					Female	21	12.1	173.2	(107.2-264.8)
Male	5	6.4	78.2	(25.2-182.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	4.9	162.1	(69.8-319.5)	Female	22	15.2	144.7	(90.6-219.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.5	nc	(nc-nc)	Male	221	206.6	107.0	(93.3-122.1)
Female	2	1.9	nc	(nc-nc)	Female	286	227.7	125.6	(111.4-141.0)
<b><u>Lung and Bronchus</u></b>									
Male	27	28.2	95.7	(63.1-139.3)					
Female	37	31.9	115.9	(81.6-159.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	18.4	113.9	(70.5-174.1)	Male	10	12.1	82.4	(39.4-151.5)
Female	14	7.2	193.3	(105.6-324.4)	Female	4	10.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.5	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	14	10.7	130.3	(71.2-218.7)
Female	73	81.6	89.5	(70.1-112.5)	Female	10	10.0	99.8	(47.8-183.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.6	nc	(nc-nc)	Male	9	9.1	99.2	(45.2-188.2)
<b><u>Colon / Rectum</u></b>					Female	3	4.2	nc	(nc-nc)
Male	19	19.9	95.3	(57.3-148.8)	<b><u>Ovary</u></b>				
Female	17	21.7	78.5	(45.7-125.7)	Female	5	7.1	70.0	(22.6-163.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	5.1	136.4	(54.7-281.1)	Male	7	6.7	105.2	(42.2-216.8)
Female	0	1.4	nc	(nc-nc)	Female	7	7.2	96.9	(38.8-199.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	85	68.3	124.4	(99.4-153.8)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.4	113.5	(36.6-264.9)
Male	18	10.7	168.3	(99.7-266.0)	Female	4	2.8	nc	(nc-nc)
Female	5	6.4	78.1	(25.2-182.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.2	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	14.2	70.2	(33.6-129.1)
Male	2	7.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	5.7	nc	(nc-nc)	Female	14	18.6	75.5	(41.2-126.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.7	74.5	(24.0-173.9)	Male	269	251.6	106.9	(94.5-120.5)
Female	2	2.3	nc	(nc-nc)	Female	238	271.5	87.7	(76.9-99.5)
<b><u>Lung and Bronchus</u></b>									
Male	26	34.2	75.9	(49.6-111.3)					
Female	34	38.6	88.2	(61.0-123.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	57	56.3	101.3	(76.7-131.2)	Male	25	37.4	66.9	(43.3-98.7)
Female	22	21.1	104.3	(65.4-158.0)	Female	28	30.9	90.7	(60.3-131.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	11.5	104.3	(53.9-182.3)	Male	10	11.6	86.0	(41.2-158.1)
Female	9	9.5	94.5	(43.1-179.5)	Female	14	9.6	146.4	(80.0-245.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	5	2.0	254.0	(81.9-592.7)	Male	38	33.4	113.7	(80.5-156.1)
Female	232	239.2	97.0	(84.9-110.3)	Female	42	29.8	141.2	(101.7-190.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	8.4	119.1	(57.0-219.1)	Male	37	27.5	134.6	(94.7-185.5)
<b><u>Colon / Rectum</u></b>					Female	9	12.6	71.5	(32.6-135.7)
Male	69	61.9	111.5	(86.8-141.1)	<b><u>Ovary</u></b>				
Female	83	64.6	128.5	(102.3-159.3)	Female	16	21.2	75.5	(43.1-122.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	16	15.3	104.4	(59.7-169.6)	Male	27	20.0	134.7	(88.7-196.0)
Female	3	4.1	nc	(nc-nc)	Female	24	21.2	113.0	(72.4-168.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	9	4.7	191.7	(87.5-363.9)	Male	165	196.4	84.0	(71.7-97.8)
Female	5	3.8	133.2	(42.9-310.8)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	13.4	96.9	(51.6-165.8)
Male	37	32.4	114.2	(80.4-157.5)	Female	7	8.3	84.2	(33.7-173.4)
Female	24	18.8	127.8	(81.9-190.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	8.6	116.1	(55.6-213.6)
Male	14	9.0	155.3	(84.8-260.6)	<b><u>Thyroid</u></b>				
Female	5	2.8	180.0	(58.0-420.1)	Male	21	15.2	138.4	(85.6-211.5)
<b><u>Leukemia</u></b>					Female	65	45.7	142.2	(109.7-181.2)
Male	19	23.2	81.8	(49.2-127.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	17.5	74.4	(39.6-127.2)	Female	42	53.9	77.9	(56.1-105.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	21	20.2	104.1	(64.4-159.1)	Male	806	760.7	106.0	(98.8-113.5)
Female	6	6.7	89.6	(32.7-195.0)	Female	848	803.7	105.5	(98.5-112.9)
<b><u>Lung and Bronchus</u></b>									
Male	134	102.2	131.1	(109.9-155.3)					
Female	126	110.0	114.5	(95.4-136.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	9.6	114.1	(56.9-204.1)	Male	4	6.3	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	0	4.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	27	36.4	74.2	(48.9-108.0)	Female	5	4.3	117.3	(37.8-273.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	1	4.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.8	nc	(nc-nc)
Male	9	10.5	85.5	(39.0-162.3)	<b><u>Ovary</u></b>				
Female	12	8.9	135.3	(69.8-236.4)	Female	6	3.2	189.8	(69.3-413.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	28	37.5	74.7	(49.6-107.9)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.3	nc	(nc-nc)
Male	9	5.7	159.1	(72.6-302.1)	Female	1	1.1	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.0	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	6.8	73.1	(23.6-170.5)
Male	4	3.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.5	nc	(nc-nc)	Female	11	8.4	131.1	(65.4-234.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	3.6	139.8	(45.0-326.2)	Male	115	133.4	86.2	(71.2-103.5)
Female	0	1.0	nc	(nc-nc)	Female	118	118.5	99.5	(82.4-119.2)
<b><u>Lung and Bronchus</u></b>									
Male	19	17.9	106.3	(64.0-166.0)					
Female	25	16.6	150.8	(97.6-222.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	29.3	133.1	(94.6-182.0)	Male	16	19.8	80.9	(46.2-131.4)
Female	12	13.0	92.6	(47.8-161.8)	Female	16	17.6	90.7	(51.8-147.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.0	115.9	(46.4-238.8)	Male	4	6.1	nc	(nc-nc)
Female	6	5.4	110.8	(40.5-241.3)	Female	6	5.8	104.3	(38.1-227.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	21	17.6	119.6	(74.0-182.8)
Female	131	138.6	94.5	(79.0-112.2)	Female	21	17.7	118.3	(73.2-180.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	4.5	175.9	(75.7-346.6)	Male	17	14.8	114.6	(66.7-183.6)
<b><u>Colon / Rectum</u></b>					Female	8	7.4	107.6	(46.3-212.1)
Male	34	32.8	103.8	(71.9-145.0)	<b><u>Ovary</u></b>				
Female	31	39.0	79.4	(54.0-112.7)	Female	16	12.3	130.1	(74.3-211.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	8.1	135.5	(67.5-242.4)	Male	14	10.6	132.1	(72.2-221.7)
Female	4	2.5	nc	(nc-nc)	Female	8	13.1	61.0	(26.3-120.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.4	nc	(nc-nc)	Male	116	105.8	109.7	(90.6-131.6)
Female	3	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	7.1	84.8	(31.0-184.6)
Male	28	17.2	162.6	(108.0-235.0)	Female	6	5.1	118.6	(43.3-258.2)
Female	11	11.0	99.6	(49.6-178.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	4.4	nc	(nc-nc)
Male	6	4.8	124.1	(45.3-270.0)	<b><u>Thyroid</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	6	8.1	73.9	(27.0-161.0)
<b><u>Leukemia</u></b>					Female	30	24.5	122.7	(82.7-175.1)
Male	26	12.0	216.3	(141.3-316.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	14	10.4	135.0	(73.8-226.6)	Female	29	31.1	93.2	(62.4-133.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	11.0	63.8	(25.5-131.4)	Male	464	403.2	115.1	(104.8-126.0)
Female	1	4.0	nc	(nc-nc)	Female	488	473.0	103.2	(94.2-112.7)
<b><u>Lung and Bronchus</u></b>									
Male	64	53.8	118.9	(91.6-151.8)					
Female	79	67.6	116.9	(92.6-145.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	3.8	156.4	(57.1-340.3)	Male	8	2.7	301.8	(129.9-594.7)
Female	0	1.5	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	32	18.1	176.7	(120.8-249.4)	Female	2	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.9	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	4.3	115.8	(37.3-270.1)	Female	3	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	20	14.0	142.8	(87.2-220.5)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	0.9	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.3	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.2	nc	(nc-nc)	Female	5	4.4	113.7	(36.7-265.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	1.5	nc	(nc-nc)	Male	70	53.8	130.2	(101.5-164.5)
Female	0	0.5	nc	(nc-nc)	Female	78	59.3	131.5	(103.9-164.1)
<b><u>Lung and Bronchus</u></b>									
Male	4	7.2	nc	(nc-nc)					
Female	10	8.4	118.6	(56.8-218.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	11.2	80.7	(36.8-153.1)
Female	0	0.1	nc	(nc-nc)	Female	3	7.7	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.5	nc	(nc-nc)					
Female	1	1.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	8.0	nc	(nc-nc)	Male	6	5.0	119.9	(43.8-261.1)
Female	4	2.7	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.5	133.6	(48.8-290.8)
Female	27	29.1	92.8	(61.2-135.1)	Female	3	3.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.6	nc	(nc-nc)
Male	4	8.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	8.3	72.2	(26.4-157.1)	Female	4	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	29	27.2	106.5	(71.3-152.9)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.9	nc	(nc-nc)
Male	4	4.4	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.8	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.0	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.2	nc	(nc-nc)	Female	6	6.5	92.8	(33.9-201.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.7	nc	(nc-nc)	Male	97	103.9	93.3	(75.7-113.9)
Female	1	0.8	nc	(nc-nc)	Female	96	98.2	97.7	(79.2-119.3)
<b><u>Lung and Bronchus</u></b>									
Male	18	14.3	126.0	(74.6-199.1)					
Female	17	13.5	125.7	(73.2-201.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	6.9	145.5	(69.7-267.7)	Male	3	5.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	6	4.4	137.4	(50.2-299.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	10	4.7	212.0	(101.5-390.0)
Female	35	35.0	99.9	(69.6-138.9)	Female	3	3.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.7	nc	(nc-nc)
Male	14	8.5	165.6	(90.4-277.8)	<b><u>Ovary</u></b>				
Female	11	8.1	136.4	(68.0-244.0)	Female	4	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	2.3	308.8	(123.7-636.2)	Male	2	2.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	22	32.2	68.4	(42.8-103.5)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.8	nc	(nc-nc)
Male	5	5.1	97.8	(31.5-228.3)	Female	0	1.0	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.4	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	7.3	123.0	(56.1-233.5)
Male	1	3.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.3	nc	(nc-nc)	Female	4	7.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.1	nc	(nc-nc)	Male	117	110.7	105.7	(87.4-126.7)
Female	1	0.9	nc	(nc-nc)	Female	114	109.6	104.0	(85.8-125.0)
<b><u>Lung and Bronchus</u></b>									
Male	14	13.4	104.4	(57.0-175.1)					
Female	15	13.6	110.4	(61.8-182.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	19	11.5	164.9	(99.2-257.4)	Female	2	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.6	nc	(nc-nc)
Male	5	3.4	145.1	(46.8-338.6)	<b><u>Ovary</u></b>				
Female	3	2.8	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	11.5	52.1	(19.0-113.3)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.8	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.7	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	1.2	nc	(nc-nc)	Male	37	42.7	86.6	(60.9-119.3)
Female	0	0.3	nc	(nc-nc)	Female	49	37.1	132.2	(97.8-174.8)
<b><u>Lung and Bronchus</u></b>									
Male	3	6.0	nc	(nc-nc)					
Female	2	5.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	9.5	157.8	(88.2-260.3)	Male	5	7.0	71.0	(22.9-165.7)
Female	7	3.7	191.6	(76.8-394.9)	Female	7	5.9	117.9	(47.2-243.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.4	nc	(nc-nc)
Female	37	47.6	77.7	(54.7-107.0)	Female	3	5.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.4	nc	(nc-nc)
Male	12	11.9	101.2	(52.2-176.7)	<b><u>Ovary</u></b>				
Female	7	11.6	60.5	(24.2-124.6)	Female	4	4.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.0	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	32	41.9	76.3	(52.2-107.8)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.5	nc	(nc-nc)
Male	8	6.7	119.2	(51.3-234.8)	Female	1	1.5	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	9.4	85.3	(36.7-168.0)
Male	7	4.2	166.8	(66.8-343.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.1	nc	(nc-nc)	Female	11	10.8	101.6	(50.7-181.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	4.3	164.3	(65.8-338.5)	Male	141	148.2	95.2	(80.1-112.2)
Female	1	1.2	nc	(nc-nc)	Female	131	152.3	86.0	(71.9-102.0)
<b><u>Lung and Bronchus</u></b>									
Male	23	18.1	127.3	(80.7-191.0)					
Female	21	19.7	106.6	(66.0-163.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	10.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	6	12.2	49.4	(18.0-107.4)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.6	nc	(nc-nc)					
Female	0	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	6.0	99.7	(36.4-217.1)	Male	5	4.4	113.2	(36.5-264.2)
Female	2	2.3	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	7	4.0	177.0	(70.9-364.6)
Female	38	31.1	122.1	(86.4-167.6)	Female	3	3.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.5	nc	(nc-nc)
Male	7	7.1	98.0	(39.3-202.0)	<b><u>Ovary</u></b>				
Female	4	7.1	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	20	26.1	76.7	(46.8-118.5)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.5	nc	(nc-nc)
Male	1	4.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.0	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	6.2	81.1	(26.1-189.3)
Male	4	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.0	nc	(nc-nc)	Female	14	7.0	199.4	(108.9-334.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	2.6	228.5	(83.4-497.4)	Male	86	92.4	93.1	(74.5-115.0)
Female	1	0.8	nc	(nc-nc)	Female	108	97.9	110.4	(90.5-133.3)
<b><u>Lung and Bronchus</u></b>									
Male	12	11.6	103.1	(53.2-180.1)					
Female	12	12.9	93.1	(48.1-162.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	12.5	128.0	(73.1-207.9)	Male	13	8.6	150.7	(80.1-257.6)
Female	3	4.9	nc	(nc-nc)	Female	4	7.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	7	7.7	90.5	(36.3-186.5)
Female	61	58.4	104.4	(79.9-134.1)	Female	5	7.1	70.5	(22.7-164.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	11	6.6	165.8	(82.7-296.8)
<b><u>Colon / Rectum</u></b>					Female	1	3.0	nc	(nc-nc)
Male	16	14.3	111.7	(63.8-181.3)	<b><u>Ovary</u></b>				
Female	15	15.3	98.2	(54.9-162.0)	Female	4	5.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	5	5.0	100.4	(32.4-234.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	58	46.3	125.3	(95.1-162.0)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	3.1	163.3	(52.6-381.1)
Male	11	7.6	144.0	(71.8-257.6)	Female	0	1.9	nc	(nc-nc)
Female	5	4.5	110.8	(35.7-258.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.2	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	10.7	84.4	(38.5-160.3)
Male	7	5.3	132.4	(53.0-272.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.1	145.8	(53.2-317.3)	Female	13	13.3	98.1	(52.2-167.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	4.9	nc	(nc-nc)	Male	219	176.3	124.2	(108.3-141.8)
Female	1	1.6	nc	(nc-nc)	Female	176	192.6	91.4	(78.4-105.9)
<b><u>Lung and Bronchus</u></b>									
Male	29	22.9	126.8	(84.9-182.1)					
Female	23	26.3	87.4	(55.4-131.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	29.0	110.3	(75.4-155.7)	Male	27	19.0	142.2	(93.7-206.9)
Female	8	9.0	88.9	(38.3-175.1)	Female	26	13.8	188.4	(123.0-276.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	5.6	142.8	(61.5-281.3)	Male	3	6.0	nc	(nc-nc)
Female	8	4.3	187.1	(80.6-368.8)	Female	4	4.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	10	16.8	59.6	(28.5-109.7)
Female	125	109.1	114.6	(95.4-136.5)	Female	18	13.0	138.3	(81.9-218.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.8	nc	(nc-nc)	Male	13	13.7	94.8	(50.5-162.2)
<b><u>Colon / Rectum</u></b>					Female	4	5.6	nc	(nc-nc)
Male	33	31.0	106.4	(73.2-149.4)	<b><u>Ovary</u></b>				
Female	34	27.3	124.7	(86.4-174.3)	Female	6	9.6	62.6	(22.9-136.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	7.8	nc	(nc-nc)	Male	7	10.3	68.0	(27.2-140.1)
Female	1	1.8	nc	(nc-nc)	Female	11	9.0	122.6	(61.1-219.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	76	100.2	75.8	(59.8-94.9)
Female	0	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	6.8	73.1	(23.6-170.6)
Male	8	16.2	49.4	(21.3-97.4)	Female	2	3.5	nc	(nc-nc)
Female	9	8.4	107.0	(48.8-203.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.8	nc	(nc-nc)
Male	5	4.6	108.2	(34.9-252.5)	<b><u>Thyroid</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	5	7.4	67.7	(21.8-158.0)
<b><u>Leukemia</u></b>					Female	22	21.0	104.7	(65.6-158.6)
Male	10	11.6	86.2	(41.3-158.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	7.6	79.4	(29.0-172.8)	Female	17	25.1	67.6	(39.4-108.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	10.4	57.8	(21.1-125.9)	Male	323	386.0	83.7	(74.8-93.3)
Female	4	3.0	nc	(nc-nc)	Female	396	358.0	110.6	(100.0-122.1)
<b><u>Lung and Bronchus</u></b>									
Male	39	52.9	73.7	(52.4-100.7)					
Female	58	48.7	119.1	(90.4-154.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	7	8.2	85.1	(34.1-175.3)	Female	0	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	2.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	2.1	292.0	(106.6-635.7)	Female	1	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	10.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	2	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	6	2.0	298.9	(109.1-650.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	26	35.0	74.3	(48.5-108.9)
Female	0	0.2	nc	(nc-nc)	Female	30	26.9	111.3	(75.1-158.9)
<b><u>Lung and Bronchus</u></b>									
Male	6	4.7	127.0	(46.4-276.4)					
Female	4	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;